A new study reveals critical insights into the role of gamma-delta T cells across 33 cancer types, shedding light on their potential as clinical biomarkers and therapeutic targets in cancer treatment.

Delhi, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Global Gamma Delta T Cell Cancer Therapy Market Opportunity and Clinical Trials Insight 2030 Report Conclusions: Global Gamma Delta T Cell Therapy Clinical ...

This new platform aims to expand Gamma-Delta T-cells effectively ... INB-619 targets CD19, a marker found on B cells involved in leukemias, lymphomas, and autoimmune conditions.

NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T ... marker broadly found on B cells ...

Adicet Bio specializes in the development of off-the-shelf gamma-delta T cell therapies for the treatment of cancer and autoimmune diseases. The company's innovative approach leverages the unique ...

ADI-001 is an allogeneic gamma delta CAR T-cell therapy that targets the B-cell antigen CD20. The Food and Drug Administration (FDA) has granted Fast Track designation to ADI-001 for the treatment ...

Boston-based Adicet’s approach to cell therapy starts with gamma delta T cells, which stands in contrast to much of the cell therapy field, which is working with alpha beta T cells. Gamma delta ...

Despite their minority status within the T cell community, gamma-delta T cells are increasingly recognized for their dual capability to engage both innate and adaptive immune responses. Moffitt ...

The platform’s first candidate, INB-619, targets CD19, a key marker broadly found on ... biopharmaceutical company developing gamma-delta (γδ) T cell-based immunotherapies for cancer patients.

A study published in Cell Press reveals the significant role of gamma-delta T cells in treatment outcomes for 33 cancer types. Researchers at Moffitt Cancer Center found that these cells ...